BTC Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

BTC Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,204	Closed	-$200K	–	256
2022 Q1	$200K	Buy	3,204 +437	+16%	+$27.4K	0.02%	258
2021 Q4	$210K	Buy	+2,767	New	+$242K	0.02%	254
2021 Q3	–	Sell	-1,436	Closed	-$233K	–	209
2021 Q2	$233K	Sell	1,436 -401	-22%	-$48.8K	0.03%	195
2021 Q1	$224K	Sell	1,837 -245	-12%	-$37K	0.03%	222
2020 Q4	$317K	Buy	+2,082	New	+$246K	0.04%	186
2018 Q4	–	Sell	-5,485	Closed	-$246K	–	177
2018 Q3	$246K	Buy	5,485 +1,162	+27%	+$60.9K	0.04%	157
2018 Q2	$258K	Buy	+4,323	New	+$246K	0.06%	129

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BTC Capital Management's CRSP Position: Q2 2022 in Review

BTC Capital Management sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 3,204 shares — an estimated $200K sold.

BTC Capital Management first reported a position in CRSP in Q2 2018 and held it in 7 quarters. The position peaked at $317K in Q4 2020. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

BTC Capital Management reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
BTC Capital Management sold 3,204 CRISPR Therapeutics shares in Q2 2022, an estimated $200K.
BTC Capital Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 7 quarters.
BTC Capital Management's CRISPR Therapeutics position peaked at $317K in Q4 2020.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on BTC Capital Management's 13F filing for Q2 2022, filed 25 Jul 2022.